Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply

Lancet. 2021 Jul 24;398(10297):300. doi: 10.1016/S0140-6736(21)01422-7.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • COVID-19 Drug Treatment*
  • Humans
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • tocilizumab